All In Biotech

NDA 022387 · United Therap

Tyvaso

Treprostinil · Inhalation · Prostacycline Vasodilator

Orphan

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jul 30, 2009

Approved uses

4

Original approval plus efficacy supplements

Registered trials

129

42 Phase 3, 15 recruiting

FAERS reports

44,108

26,272 serious, 5,847 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 14, 2026.

Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 ) 1.1 Pulmonary Arterial Hypertension Tyvaso is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities. While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration [see Clinical Studies (14) ] . 1.2 Pulmonary Hypertension Associated with ILD Tyvaso is indicated for the treatment of pulmonary hypertension associated...

Mechanism: Treprostinil is a prostacyclin analogue. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TYVASO · TREPROSTINIL 0.6MG/ML · SOLUTION, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Treprostinil" as an intervention, any sponsor and status, largest first.

All 129 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea8,544
  • cough6,585
  • headache6,381
  • diarrhoea4,111
  • dizziness3,983
  • nausea3,945
  • fatigue3,824
  • death3,423
  • off label use3,291
  • pneumonia2,360
  • hypotension2,306
  • oxygen saturation decreased2,113

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20063
20071
20082
20099
2010253
2011805
2012911
2013811
20144,869
20154,317
20163,283
20172,627
20182,678
20192,668
20202,388
20212,920
20223,965
20233,406
20243,084
20253,086
20262,021

Recalls

1 FDA enforcement reports for this application.

  • Aug 14, 2018 · Class III · Terminated

    Defective Delivery System: Water ingress through the lower water cup sensor of the device.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Tyvaso* (Treprostinil*) · HCPCS J7686

2024 spending

$183M

Beneficiaries

1,226

8,988 claims

Per beneficiary

$149,284

2024 ASP limit $743.92 per unit

View as table
YearSpending
2020$217,247,290
2021$253,875,006
2022$256,380,566
2023$205,576,762
2024$183,021,609

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 116 on PubMed

Sponsor: United Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.